Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Pharmaceuticals LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.625p +0.70% 90.00p 88.50p 90.25p 90.00p 86.00p 89.00p 123,263 16:35:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 23.1 -144.9 -48.0 - 299.31

Circassia Share Discussion Threads

Showing 901 to 924 of 925 messages
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
18/4/2017
07:35
Dead again.
bulltradept
17/3/2017
10:11
From the DJN report - "The deal is expected to improve earnings for Circassia after one year and to be broadly cash neutral for three years, then cash generative."
bandflex
17/3/2017
09:51
Silly me, I looked at that chart assumed AIM.
bandflex
17/3/2017
08:56
Forget AIM. That's irrelevant to the investment case
mirabeau
17/3/2017
08:54
Have to put it down to the vagaries of the AIM market.
bandflex
17/3/2017
08:51
Your guess is as good as mine. it looks like a change in direction away from allergies. either way the market loves today's news and I bet the agreement suits both parties other than that, I am clueless...
mirabeau
17/3/2017
08:42
It will cost CIR up to $230m, plus royalties, and Circassia will make R&D contributions of up to US$62.5 million payable to AstraZeneca as deferred payments.
bandflex
17/3/2017
08:40
Interesting, but why is it going up. CIR are buying the rights from AStraZeneca to sell two AstraZeneca products not the other way around.
bandflex
17/3/2017
07:28
Interesting news this morning
mirabeau
17/3/2017
07:12
Nice r n s watch it grow
jammytass
01/10/2016
10:33
This is not making any recovery and serves as a reminder of the risks in this type of investment. Probably better to invest via a Fund to spread risk.
888icb
23/6/2016
05:08
Circassia Pharmaceuticals extended Tuesday’s rebound 23rd June 2016 http://bit.ly/28P3mk7 Circassia Pharmaceuticals, which on Monday tumbled more than 60 per cent after its cat allergy trial collapsed, extended Tuesday’s rebound, climbing 8.7 per cent, or 8.5p to 105.5p.
dice1950
21/6/2016
20:53
Peel Hunt said: Circassia uncertainty overhang medium-term unless a strategic bid emerges. 21st June 2016 http://goo.gl/eVVnki
dice1950
21/6/2016
09:20
RBC Capital Markets, Peel Hunt Circassia slashed after poor test results - http://www.directorstalk.com/circassia-slashed-poor-test-results/ … - #CIR
dice1950
21/6/2016
09:18
Tempus in today's Times says its a buy. http://www.thetimes.co.uk/edition/business/dividend-safe-with-grid-lights-staying-on-whw22qwzb When Circassia came to the market in 2014 at 310p a share, it was seen as the owner of a promising but unproven treatment for allergies, including hay fever. En route the company paid £239 million for a couple of companies making treatments for asthma and pulmonary disease, raising fresh funds at 288p a share. The first widescale trials of that allergy treatment for people allergic to cats have been an unmitigated disaster. Put simply, sufferers given the treatment did well but so did those given a placebo. This is frankly baffling. Circassia is giving up trials of the same treatment for sufferers of hay fever and those allergic to ragweed, though two others are sufficiently well advanced that there is no point in abandoning them. The conclusion of these may give an idea why the feline trials went so badly and whether the treatment has any value whatsoever. This leaves the company with those asthma products, several of which are on the market. If the study was baffling, the market’s response was equally so. Circassia shares lost two thirds of their value, falling 179¼p to 91p. This gives it a market capitalisation of £257 million. Tot up the cost of those acquisitions and the cash in the bank and you get to £379 million. This suggests that the fall in the price is wildly overdone, assuming those businesses bought have the value ascribed to them, with the original allergy treatment assigned no value whatsoever. Any biotech company is always going to be speculative, but this looks a good gamble. MY ADVICE Buy WHY Risky, but the share price fall looks overdone
paleje
21/6/2016
08:37
Dead cat bounce.......
muffster
20/6/2016
21:40
Numis said: Circassia Pharmaceuticals has collapsed 64% 20th June 2016 http://goo.gl/4x87QG
dice1950
20/6/2016
19:38
Can't see this bouncing till the low 50's
investment dave
20/6/2016
18:01
Oh dear looks like 40p is on the cards cash at the bank valuation.
catswhiskas
20/6/2016
17:33
Also Woody sells he BT stake why?
montyhedge
20/6/2016
17:32
Never admit that you were wrong or the game's all over hxxps://woodfordfunds.com/blog/circassia-reaction/?utm_source=blog-alert&utm_medium=email&utm_campaign=circassia-reaction
mammyoko
20/6/2016
17:16
https://woodfordfunds.com/print/?pageid=6586
kooba
20/6/2016
14:23
will this bounce?
1toad
20/6/2016
10:53
Oh dear, Woody's lost another £100m of other people's money
mammyoko
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170724 18:50:31